Infusional C-myb ASODN in Advanced Hematologic Malignancies
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether C-myb Antisense (AS) Oligonucleotides
(ODNs)is a possible treatment modality for advanced hematologic malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania